News
German Biotech Leaders Identify Cross-Border Investment ...
www.bionity.com
Comparing business conditions for biotech companies in Germany and the United States, Thomas Christely added: "Germany has significantly lower operating costs." The panelists agreed that the cost advantages in Germany ...
SR Pharma PLC | Publication of Circular to Shareholders ...www.investegate.co.uk › articlePrint
www.investegate.co.uk
... Chairman Thomas Christely Melvyn Davies Finance Director Mulier Capital Bioscience Managers Limited Advisers to SR Pharma Advisers to ...
Investegate |SR Pharma PLC Announcements | SR Pharma PLC: Publication...
www.investegate.co.uk
Investegate announcements from SR Pharma PLC, Publication of Circular to Shareholders
Isis Pharma and atugen AG enter patent license agreementPharmabiz.com
test.pharmabiz.com
... offer target validation services, including the elucidation of disease pathways to partners," said Thomas Christely, atugen's Chief Operating Officer. › news
sortiert nach Relevanz / Datum